A5012603847- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Melanoma and MAPK Pathways
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Cell Image Analysis Techniques
- bioluminescence and chemiluminescence research
- Ubiquitin and proteasome pathways
- Protein Degradation and Inhibitors
- Childhood Cancer Survivors' Quality of Life
- Immune Cell Function and Interaction
- Cytokine Signaling Pathways and Interactions
- Glycosylation and Glycoproteins Research
- Phagocytosis and Immune Regulation
- RNA Interference and Gene Delivery
- Genetic factors in colorectal cancer
- Multiple Myeloma Research and Treatments
- Neuroblastoma Research and Treatments
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Cell death mechanisms and regulation
- Cancer-related Molecular Pathways
- Glioma Diagnosis and Treatment
University Hospital Carl Gustav Carus
2024-2025
National Center for Tumor Diseases
2025
Technische Universität Dresden
2025
Otto-von-Guericke University Magdeburg
2022-2024
Kiel University
2015-2024
Icahn School of Medicine at Mount Sinai
2008-2023
Pediatrics and Genetics
2023
Deutsche Forschungsgemeinschaft
2023
University Hospital Magdeburg
2022
Universitätskinderklinik
2022
The pathways that allow quiescent disseminated cancer cells to survive during prolonged dormancy periods are unknown. Here, we identify the transcription factor ATF6α as a pivotal survival for but not proliferative squamous carcinoma cells. is essential adaptation of dormant chemotherapy, nutritional stress, and, most importantly, in vivo microenvironment. Mechanism analysis showed MKK6 and p38α/β contribute regulating nuclear translocation transcriptional activation Downstream, induces...
Purpose Somatic deletions that affect the lymphoid transcription factor–coding gene IKZF1 have previously been reported as independently associated with a poor prognosis in pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). We now refined prognostic strength of by analyzing effect co-occurring deletions. Patients and Methods The analysis involved 991 patients BCP ALL treated Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster (AIEOP-BFM) 2000...
IKZF1 gene deletions have been associated with a poor outcome in pediatric precursor B-cell acute lymphoblastic leukemia. To assess the prognostic relevance of for patients treated on Berlin-Frankfurt-Münster Study Group trial ALL-BFM 2000, we screened 694 diagnostic leukemia samples by Multiplex Ligation-dependent Probe Amplification. Patients whose leukemic cells bore had lower 5-year event-free survival (0.69±0.05 vs. 0.85±0.01; P
Abstract The stress-activated kinase p38 plays key roles in tumor suppression and induction of cell dormancy. However, the mechanisms behind these functions remain poorly understood. Using computational tools, we identified a transcription factor (TF) network regulated by p38α/β required for human squamous carcinoma quiescence vivo. We found that transcriptionally regulates core 46 genes includes 16 TFs. Activation induced expression TFs p53 BHLHB3, while inhibiting c-Jun FoxM1 expression....
The proteasome inhibitor bortezomib (Velcade) effectively eradicates multiple myeloma (MM) cells, partly by activating endoplasmic reticulum (ER) stress apoptotic signaling. However, MM recurrences in bortezomib-treated patients are invariable. We have shown that ER signaling can also induce growth arrest and survival cancer cells. Thus, we hypothesized therapy could quiescence of residual contributing to disease recurrence. Here, report inhibition with MG-132 or results a surviving cell...
The fusion gene MLL/AF4 defines a high-risk subtype of pro-B acute lymphoblastic leukemia. Relapse can be associated with lineage switch from to myeloid leukemia, resulting in poor clinical outcomes caused by resistance chemotherapies and immunotherapies. In this study, the relapses shared oncogene breakpoints their matched lymphoid presentations originated various differentiation stages immature progenitors through committed B-cell precursors. Lineage switching is linked substantial changes...
Antibody-dependent cellular phagocytosis (ADCP) by macrophages, an important effector function of tumor targeting antibodies, is hampered 'Don´t Eat Me!' signals such as CD47 expressed cancer cells. Yet, human leukocyte antigen (HLA) class I expression may also impair ADCP engaging immunoglobulin-like receptor subfamily B (LILRB) member 1 (LILRB1) or LILRB2. Analysis different lymphoma cell lines revealed that the ratio CD20 to HLA surface molecules determined sensitivity combination...
Antibodies of IgA isotype effectively engage myeloid effector cells for cancer immunotherapy. Here, we describe preclinical studies with an Fc engineered IgA2m(1) antibody containing the variable regions EGFR cetuximab. Compared wild-type IgA2m(1), molecule lacked two N-glycosylation sites (N166 and N337), free cysteines (C311 C472), contained a stabilized heavy light chain linkage (P221R mutation). This novel displayed improved production rates biochemical properties compared IgA. In vitro,...
Central nervous system infiltration and relapse are poorly understood in childhood acute lymphoblastic leukemia. We examined the role of zeta-chain-associated protein kinase 70 preclinical models central leukemia performed correlative studies patients. Zeta-chain-associated expression cells was modulated using short hairpin ribonucleic acid-mediated knockdown or ectopic expression. show that regulates CCR7/CXCR4 via activation extracellular signal-regulated kinases. High resulted a higher...
ABL-class fusions other than BCR-ABL1 characterize around 2-3% of precursor B-cell acute lymphoblastic leukemia. Case series indicated that patients suffering from these subtypes have a dismal outcome and may benefit the introduction tyrosine kinase inhibitors. We analyzed clinical characteristics 46 fusion positive cases treated according to AIEOP-BFM (Associazione Italiana di Ematologia-Oncologia Pediatrica-Berlin-Frankfurt-Münster) ALL 2000 2009 protocols; 13 them received inhibitor (TKI)...
// Hendrik Fritsche 1, * , Thorsten Heilmann 2, Robert J. Tower 3, Charlotte Hauser 4 Anja von Au 5 Doaa El-Sheikh 1 Graeme M. Campbell 3 Göhkan Alp Denis Schewe 6 Sebastian Hübner Sanjay Tiwari Daniel Kownatzki Susann Boretius Dieter Adam 7 Walter Jonat 2 Thomas Becker Claus C. Glüer Margot Zöller Holger Kalthoff Christian Schem Anna Trauzold 4, Division of Molecular Oncology, Institute for Experimental Cancer Research, CCC-North, University Kiel, Germany Department...
Abstract Central nervous system (CNS) involvement remains a challenge in the diagnosis and treatment of acute lymphoblastic leukemia (ALL). In this study, we identify CD79a (also known as Igα), signaling component preB cell receptor (preBCR), to be associated with CNS-infiltration –relapse B-cell precursor (BCP)-ALL patients. Furthermore, show that downregulation hampers engraftment cells different murine xenograft models, particularly CNS.
Abstract Background The prognosis for Li–Fraumeni syndrome (LFS) patients with medulloblastoma (MB) is poor. Comprehensive clinical data this patient group lacking, challenging the development of novel therapeutic strategies. Here, we present and molecular on a retrospective cohort pediatric LFS MB patients. Methods In multinational, multicenter study, under 21 years class 5 or 4 constitutional TP53 variants were included. mutation status, methylation subgroup, treatment, progression free-...